According to filings with the U.S. Securities and Exchange Commission, Bectas Therapeutics is raising up to $10 Million in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Ronan O’hagan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Bectas Therapeutics
Bectas Therapeutics is a preclinical-stage biotech company developing monoclonal antibody therapies for cancer accompanied by biomarkers to identify patients that will most benefit from each Bectas therapeutic antibody. Our programs combine monoclonal antibodies that exhibit best-in-class pre-clinical activity with precision insights that enable first-in-class therapies to serve patients across multiple cancer indications. Our mission is to bring precision to immune-therapies for cancer in order to fully realize the potential of the immune system to deliver curative therapies for people living with cancer.

To learn more about Bectas Therapeutics, visit http://bectastx.com/
Bectas Therapeutics Linkedin Page:

Contact:
Ronan O’hagan, President and Chief Executive Officer
617-834-3476
https://www.linkedin.com/in/ronanohagan/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.